Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma
Brief Summary: The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo. Tiotropium inhalation solution delivered by the Respimat® inhaler will be examined as add-on controller therapy on top of usual care in patients with severe persistent asthma. The primary objective of each trial is to evaluate the long term efficacy of tiotropium over placebo on top of usual care in patients with severe persistent asthma as determined by pulmonary function testing, effects on asthma exacerbations, effects on quality of life, on asthma control and health care resource utilisation. The secondary objective of each trial is to compare the long term safety of tiotropium with placebo in this patient population.


Options:
A: Arm Label: ADVAIR 100/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 100/50mcg | Arm Label: ADVAIR 250/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 250/50mcg | Arm Label: FLOVENT 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 100mcg | Arm Label: FLOVENT 250mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 250mcg | Intervention Type: DRUG; Name: ADVAIR 100/50mcg; Assigned to Arm(s): ADVAIR 100/50mcg | Intervention Type: DRUG; Name: ADVAIR 250/50mcg; Assigned to Arm(s): ADVAIR 250/50mcg | Intervention Type: DRUG; Name: FLOVENT 100mcg; Assigned to Arm(s): FLOVENT 100mcg | Intervention Type: DRUG; Name: FLOVENT 250mcg; Assigned to Arm(s): FLOVENT 250mcg
B: Arm Label: QVM149 150/50/160 µg o.d.; Type: EXPERIMENTAL; Interventions: Drug: QVM149 150/50/160 | Arm Label: QVM149 150/50/80 µg o.d.; Type: EXPERIMENTAL; Interventions: Drug: QVM149 150/50/80 | Arm Label: QMF149 150/320 µg o.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: QMF149 150/320 | Arm Label: QMF149 150/160 µg o.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: QMF149 150/160 | Arm Label: Salmeterol/fluticasone 50/500 μg b.i.d.; Type: ACTIVE_COMPARATOR; Interventions: Drug: salmeterol/fluticasone | Intervention Type: DRUG; Name: QVM149 150/50/160; Assigned to Arm(s): QVM149 150/50/160 µg o.d. | Intervention Type: DRUG; Name: QVM149 150/50/80; Assigned to Arm(s): QVM149 150/50/80 µg o.d. | Intervention Type: DRUG; Name: QMF149 150/320; Assigned to Arm(s): QMF149 150/320 µg o.d. | Intervention Type: DRUG; Name: QMF149 150/160; Assigned to Arm(s): QMF149 150/160 µg o.d. | Intervention Type: DRUG; Name: salmeterol/fluticasone; Assigned to Arm(s): Salmeterol/fluticasone 50/500 μg b.i.d.
C: Arm Label: tiotropium 5mcg/day; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5mcg/day | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium 5mcg/day; Assigned to Arm(s): tiotropium 5mcg/day | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID

Answer: C